TECON BIOLOGY CO.LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.63 CNY | -1.29% |
|
+5.24% | -13.00% |
| May. 10 | Tecon Biology's April Pig Sales Revenue Fall 9% | MT |
| Apr. 29 | TECON BIOLOGY Co.LTD Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The company has attractive valuation levels with a low EV/sales ratio compared with its peers.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company does not generate enough profits, which is an alarming weak point.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Food Processing
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -13.00% | 1.44B | - | ||
| -2.39% | 275B | A- | ||
| -1.70% | 95.5B | C+ | ||
| -2.00% | 44.01B | C+ | ||
| +9.84% | 41.41B | B- | ||
| +1.40% | 41.13B | B- | ||
| +8.54% | 39.91B | B- | ||
| -12.79% | 31.14B | B- | ||
| -4.77% | 29.23B | A | ||
| +14.15% | 25.25B | A- |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- 002100 Stock
- Ratings TECON BIOLOGY Co.LTD